Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response

被引：0
|
作者：
Racke, F
Allan, RW
Miller, C
Weir, EG
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[2] St Agnes Hosp, Baltimore, MD USA
来源：
MODERN PATHOLOGY | 2005年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1148
引用
收藏
页码：248A / 248A
页数：1
相关论文
共 50 条
  • [41] Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
    Atallah, E
    Talpaz, M
    O'brien, S
    Rios, MB
    Guo, JQ
    Arlinghaus, R
    Fernandes-Reese, S
    Kantarjian, H
    CANCER, 2002, 94 (11) : 2996 - 2999
  • [42] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [43] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [44] Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)
    Salamanczuk, Z.
    Jakobczyk, M.
    Sacha, T.
    Skotnicki, A. B.
    CHROMOSOME RESEARCH, 2005, 13 : 171 - 171
  • [45] Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ottman, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Niederwieser, D
    Ben-Am, M
    Gathmann, I
    Ford, J
    Druker, BJ
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [46] Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia
    Lugli, A
    Ebnoether, M
    Cogliatti, SB
    Gratwohl, A
    Passweg, J
    Hess, U
    Korte, W
    Hawle, H
    Tinguely, M
    Borisch, B
    Mach-Pascual, S
    Von Juergensonn, S
    Tichelli, A
    Dirnhofer, S
    HUMAN PATHOLOGY, 2005, 36 (01) : 91 - 100
  • [47] Hematologic and cytogenetic response to imatinib mesylate in chronic myeloid leukemia
    Narayanan, G.
    Chacko, D. J.
    Koshy, A. A.
    Soman, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S18 - S18
  • [48] Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Hwang, Yu-Yan
    Tse, Eric
    So, Jason C. C.
    Wan, Thomas S. K.
    Kwong, Yok-Lam
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 302 - 305
  • [49] Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate
    Espinet, Blanca
    Carla Oliveira, Ana
    Boque, Concepcion
    Domingo, Alicia
    Alonso, Esther
    Sole, Francesc
    HAEMATOLOGICA, 2005, 90 (04) : 556 - 558
  • [50] The type of the bcr-abl transcript predicts the cytogenetic responses in chronic myelogenous leukemia patients treated with Glivec(STI571).
    Plouzeau, C
    Petinay, P
    Guilhot, J
    Brizard, F
    Bourmeyster, N
    Kitzis, A
    Brizard, A
    Bertaud, P
    Guilhot, F
    BLOOD, 2001, 98 (11) : 266B - 266B
12345